Despite its relationship to CTCF and its location within a commonly amplified genomic region, recent findings in melanoma, ovarian, prostate, and bladder carcinomas [14], [20], [22] appear to controvert a broad tumorigenic role for BORIS. The gene discussed is CTCFL; the disease is melanoma.